Geert C. Mudde

The Swiss Institute of Bioinformatics is an academic not-for-profit organization based in Basel, Switzerland. The institute provides over 160 high-quality databases and software tools to the life science community. Its mission is to lead and coordinate the field of bioinformatics. SIB experts and resources are involved in developing dedicated data services, analysis tools, and improving knowledge sharing to fight the COVID-19 pandemic. The institute has established close partnerships and collaborations with leading institutions at national and international levels. SIB values equality, diversity, and inclusion and trains the next generation of bioinformaticians to ensure that life scientists make the best use of bioinformatics and SIB's resources.

Part of Novartis AG, Sandoz AG is a Swiss company that develops generic medicines and biosimilars. The company is based in Basel, Switzerland.

Part of Pfizer Inc., Parke-Davis & Co. Ltd. is a British pharmaceutical company. The company is based in St. Helier, UK.

Ingenium Pharmaceuticals GmbH operates as a biopharmaceutical company specializing in the development of small molecule drugs. They develop inhibitors and ligands targeting key enzymes such as proteases and kinases. Their therapeutic compounds are used for the treatment of memory-related and chronic inflammatory disorders. Their focus areas cover human therapeutics, vivo pharmacology, and disease pathology. The company was founded in 1998 and is headquartered in Munich, Germany.

igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH develops biological products to treat cancer and other diseases. It focuses on cancer immunotherapies designed to prevent or delay the formation of metastases in cancer of epithelial origin, including colorectal, breast and lung cancer. Founded in 1999, the company is headquartered in Vienna, Austria.

Baxter BioScience Corp. provides biopharmaceutical and vaccines services. It offers a portfolio of therapeutic proteins derived from either human plasma or recombinant technology. The company is headquartered in Beltsville, MD.

F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria.